Sale

Antiplatelet Drugs Market

Global Antiplatelet Drugs Market Share, Size, Analysis, Trends: By Drug: Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamole, Ticlopidine, Abciximab, Tirofiban, Others; By Drug Class: Platelet Aggregation Inhibitors, Others; By Application; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Antiplatelet Drugs Market Outlook

The global antiplatelet drugs market size attained a value of USD 2.37 billion in 2023 driven by the advancements in the pharmaceutical industry and the increasing cases of thrombosis, both arterial and venous. The market is anticipated to grow at a CAGR of 7.8% during the forecast period of 2024-2032 to attain a value of USD 4.66 billion by 2032.

 

Global Antiplatelet Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to Dominate the Global Antiplatelet Drugs Industry

North America is the leading region in the global market for antiplatelet drugs. The region accounts for a significant share in the industry owing to the increasing penetration of key players in the region and the growing investments in clinical trials for antiplatelet drugs. Further, the presence of a large number of patients suffering from myocardial infarction and ischaemic strokes across the region is also aiding the industry growth. In the United States, around 800,000 individuals suffer from stroke every year, out of which 87% are ischaemic strokes. Thus, the growing prevalence of these diseases is leading to an increased demand for antiplatelet drugs. Meanwhile, the Asia Pacific is expected to witness a robust growth over the forecast period owing to the rising investments in R&D activities and the increasing government initiatives to reduce the number of deaths caused by thrombotic cardiovascular disease.

 

Antiplatelet Drugs: Market Segmentation

Antiplatelet drug belongs to a class of pharmaceuticals that decrease platelet aggregation, thus, preventing the formation of thrombus. These drugs are often referred to as platelet aggregation inhibitors. They help prevent blood cells (platelets) from clumping together to form a clot, thereby, decreasing the formation of potentially harmful blood clots. They show high efficacy in the arterial circulation, where anticoagulants are less effective. Antiplatelet drugs are most commonly used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disorder.

 

Global Antiplatelet Drugs Market By Distribution Channel

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By drug, the market is divided into:

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Dipyridamole
  • Ticlopidine
  • Abciximab
  • Tirofiban
  • Others

On the basis of drug class, the industry can be segmented into:

  • Platelet Aggregation Inhibitors
  • Glycoprotein Platelet Inhibitors
  • Protease-Activated Receptor-1 Antagonists
  • Others

Based on applications, the industry can be categorised into:

  • Myocardial Infraction
  • Percutaneous Coronary Interventions
  • Angioplasty
  • Arterial Thrombosis
  • Dental Surgeries
  • Others

The different routes of administration of antiplatelet drugs are:

  • Oral
  • Injectable

The various distribution channels of the product are:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Antiplatelet Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Advancements in the Pharmaceuticals Sector and the Growing Prevalence of Thrombosis to Bolster the Growth of the Antiplatelet Drugs Industry

The global market for antiplatelet drugs is being driven by the advancements in the pharmaceutical industry and the increasing cases of thrombosis, both arterial and venous. The incidences of venous thrombosis have escalated rapidly in the twenty-first century. Further, in patients with certain medical conditions, prevention and treatment of arterial thrombosis is particularly essential, as it can increase the chances of thrombosis or thromboembolism, which may lead to heart attack, pulmonary embolism, or stroke. Treatment of established arterial thrombosis involves the utilisation of antiplatelet drugs and thrombolytic therapy. These drugs are also essential for an individual who has undergone a heart surgery (especially prosthetic replacement heart valve). Thus, an increase in the number of patients undergoing heart surgery is also aiding the market growth. Other factors like increasing sedentary lifestyles, the proliferation of anticoagulant/antithrombotic drugs, rising geriatric population, and favourable government initiatives are further propelling the industry forward. Over the forecast period, the increasing R&D activities are expected to further contribute to the industry growth.

 

Key Industry Players in the Global Antiplatelet Drugs Market

The report gives a detailed analysis of the following key players in the global antiplatelet drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Glenmark Pharmaceuticals Ltd.
  • Sanofi SA
  • Pfizer Inc.
  • Baxter International Inc.
  • Bayer AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug
  • Drug Class
  • Application
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Drug
  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Dipyridamole
  • Ticlopidine
  • Abciximab
  • Tirofiban
  • Others
Breakup by Drug Class
  • Platelet Aggregation Inhibitors
  • Glycoprotein Platelet Inhibitors
  • Protease-Activated Receptor-1 Antagonists
  • Others
Breakup by Application
  • Myocardial Infraction
  • Percutaneous Coronary Interventions
  • Angioplasty
  • Arterial Thrombosis
  • Dental Surgeries
  • Others
Breakup by Route of Administration
  • Oral
  • Injectables
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Glenmark Pharmaceuticals Ltd.
  • Sanofi SA
  • Pfizer Inc.
  • Baxter International Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Bausch Health Companies Inc.
  • Johnson & Johnson Private Limited
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED
  • Otsuka America Pharmaceutical, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Genentech, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Antiplatelet Drugs Market Overview 

    3.1    Global Antiplatelet Drugs Market Historical Value (2017-2023) 
    3.2    Global Antiplatelet Drugs Market Forecast Value (2024-2032)
4    Global Antiplatelet Drugs Market Landscape
    4.1    Global Antiplatelet Drugs Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Antiplatelet Drugs Product Landscape
        4.2.1    Analysis by Drug
        4.2.2    Analysis by Drug Class
        4.2.3    Analysis by Application
        4.2.4    Analysis by Route of Application
        4.2.5    Analysis by Distribution Channel
5    Global Antiplatelet Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Antiplatelet Drugs Market Segmentation 
    6.1    Global Antiplatelet Drugs Market by Drug
        6.1.1    Market Overview
        6.1.2    Aspirin
        6.1.3    Clopidogrel
        6.1.4    Ticagrelor
        6.1.5    Prasugrel
        6.1.6    Dipyridamole
        6.1.7    Ticlopidine
        6.1.8    Abciximab
        6.1.9    Tirofiban
        6.1.10    Others
    6.2    Global Antiplatelet Drugs Market by Drug Class
        6.2.1    Market Overview
        6.2.2    Platelet Aggregation Inhibitors
        6.2.3    Glycoprotein Platelet Inhibitors
        6.2.4    Protease-Activated Receptor-1 Antagonists
        6.2.5    Others
    6.3    Global Antiplatelet Drugs Market by Application
        6.3.1    Market Overview
        6.3.2    Myocardial Infraction
        6.3.3    Percutaneous Coronary Interventions
        6.3.4    Angioplasty
        6.3.5    Arterial Thrombosis
        6.3.6    Dental Surgeries
        6.3.7    Others
    6.4    Global Antiplatelet Drugs Market by Route of Administration
        6.4.1    Market Overview
        6.4.2    Oral
        6.4.3    Injectables
    6.5    Global Antiplatelet Drugs Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Retail Pharmacy
        6.5.4    Online Pharmacy
        6.5.5    Others
    6.6    Global Antiplatelet Drugs Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Antiplatelet Drugs Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Antiplatelet Drugs Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Antiplatelet Drugs Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Antiplatelet Drugs Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Antiplatelet Drugs Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis 
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    Glenmark Pharmaceuticals Ltd.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Sanofi SA
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Pfizer Inc.
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Baxter International Inc.
        18.4.1    Financial Analysis
        18.4.2    Financial Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Bayer AG
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    F. Hoffmann-La Roche Ltd.
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Teva Pharmaceutical Industries Ltd.
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Mylan N.V.
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Bausch Health Companies Inc. 
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Johnson & Johnson Private Limited
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Bristol-Myers Squibb Company
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    DAIICHI SANKYO COMPANY, LIMITED
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Otsuka America Pharmaceutical, Inc.
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Eli Lilly and Company
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    AbbVie Inc.
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
    18.16    Genentech, Inc.
        18.16.1    Financial Analysis
        18.16.2    Product Portfolio
        18.16.3    Demographic Reach and Achievements
        18.16.4    Mergers and Acquisitions
        18.16.5    Certifications
19    Global Antiplatelet Drugs Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Globally, Antiplatelet Drugs market reached a value of USD 2.37 billion in 2023.

The market is projected to expand at a CAGR of 7.8% from 2023 to 2031, growing to USD 4.66 billion by 2032.

The major drivers of the industry, such as the advancements in the pharmaceutical sector, increasing prevalence of thrombotic cardiovascular disease, increasing geriatric population, proliferation of anticoagulant/antithrombotic drugs, favourable government initiatives, and busy lifestyles, are expected to aid the market growth.

The key market trends guiding the growth of the industry include the growing investments by the key players in the research and development of antiplatelet drugs.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading drugs in the market are aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole, ticlopidine, abciximab, and tirofiban, among others.

The major drug classes in the industry are platelet aggregation inhibitors, glycoprotein platelet inhibitors, and protease-activated receptor-1 antagonists, among others.

The significant application segments in the market are myocardial infraction, percutaneous coronary interventions, angioplasty, arterial thrombosis, and dental surgeries, among others.

The leading routes of administration of antiplatelet drugs in the industry are oral and injectable.

The major distribution channels in the market are hospital pharmacy, retail pharmacy, and online pharmacy, among others.

The major players in the industry are Glenmark Pharmaceuticals Ltd., Sanofi SA, Pfizer Inc., Baxter International Inc., and Bayer AG, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER